Sabby Management’s Actinium Pharmaceuticals ATNM Stock Holding History

Sabby Management’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-73,366	Closed	-$386K	–	151
2021 Q4	$441K	Buy	73,366 +46,878	+177%	+$352K	0.06%	112
2021 Q3	$235K	Buy	+26,488	New	+$184K	0.03%	139
2020 Q3	–	Sell	-32,410	Closed	-$357K	–	132
2020 Q2	$342K	Buy	32,410 +11,682	+56%	+$88.5K	0.07%	67
2020 Q1	$121K	Sell	20,728 -88,463	-81%	-$628K	0.05%	60
2019 Q4	$713K	Sell	109,191 -184,059	-63%	-$1.27M	0.2%	25
2019 Q3	$2.02M	Buy	293,250 +15,126	+5%	+$105K	1.09%	12
2019 Q2	$2.05M	Buy	+278,124	New	+$2.79M	2.58%	6
2018 Q2	–	Sell	-66,590	Closed	-$729K	–	149
2018 Q1	$729K	Buy	+66,590	New	+$1.13M	0.09%	82
2017 Q4	–	Sell	-81,137	Closed	-$1.4M	–	162
2017 Q3	$1.4M	Buy	+81,137	New	+$1.78M	0.09%	66
2017 Q1	–	Sell	-28,954	Closed	-$760K	–	268
2016 Q4	$760K	Sell	28,954 -17,134	-37%	-$536K	0.04%	164
2016 Q3	$1.87M	Buy	+46,088	New	+$2.37M	0.07%	134
2015 Q4	–	Sell	-2,281	Closed	-$121K	–	325
2015 Q3	$121K	Buy	+2,281	New	+$152K	0.01%	360

Other funds holding ATNM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sabby Management's ATNM Position: Q1 2022 in Review

Sabby Management sold out of Actinium Pharmaceuticals (ATNM) in Q1 2022, closing a stake of 73,366 shares — an estimated $386K sold.

Sabby Management first reported a position in ATNM in Q3 2015 and held it in 12 quarters. The position peaked at $2.05M in Q2 2019. 38 funds tracked by Wall St. Rank hold ATNM as of Q1 2022.

Sabby Management reported no remaining Actinium Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Sabby Management sold 73,366 Actinium Pharmaceuticals shares in Q1 2022, an estimated $386K.
Sabby Management first reported a position in Actinium Pharmaceuticals in Q3 2015 and held it in 12 quarters.
Sabby Management's Actinium Pharmaceuticals position peaked at $2.05M in Q2 2019.
38 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2022.

Based on Sabby Management's 13F filing for Q1 2022, filed 16 May 2022.